Abstract
Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1139-1146 |
| Number of pages | 8 |
| Journal | Reviews of Infectious Diseases |
| Volume | 12 |
| Issue number | 6 |
| State | Published - 1990 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Microbiology (medical)
Cite this
Molecular mechanisms of action of ribavirin. / Patterson, J. L.; Fernandez-Larsson, R.
In: Reviews of Infectious Diseases, Vol. 12, No. 6, 1990, p. 1139-1146.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Molecular mechanisms of action of ribavirin
AU - Patterson, J. L.
AU - Fernandez-Larsson, R.
PY - 1990
Y1 - 1990
N2 - Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.
AB - Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.
UR - http://www.scopus.com/inward/record.url?scp=0025203460&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025203460&partnerID=8YFLogxK
M3 - Article
C2 - 2267489
AN - SCOPUS:0025203460
VL - 12
SP - 1139
EP - 1146
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 6
ER -